A randomised controlled trial evaluating renal protective effects of selenium with vitamins A, C, E, verapamil, and losartan against extracorporeal shockwave lithotripsy-induced renal injury

2016 ◽  
Vol 119 (1) ◽  
pp. 142-147 ◽  
Author(s):  
Ahmed R. El-Nahas ◽  
Mohamed M. Elsaadany ◽  
Diaa-Eldin Taha ◽  
Ahmed M. Elshal ◽  
Mohamed Abo El-Ghar ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Renal Injury ◽  
Controlled Trial ◽  
Extracorporeal Shockwave Lithotripsy ◽  
Shockwave Lithotripsy ◽  
Protective Effects ◽  
Extracorporeal Shockwave ◽  
Randomised Controlled

scholarly journals Comparison between prolozone therapy and extracorporeal shockwave therapy in management of pain and function in resistant cases of lateral epicondylitis: a randomised controlled trial

2020 ◽  
Vol 7 (8) ◽  
pp. 1216
Author(s):  
Margaret Chabungbam ◽  
Akoijam Joy Singh ◽  
Longjam Nilachandra Singh ◽  
Yumnam Ningthemba ◽  
Sreejith C. ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Tennis Elbow ◽  
Controlled Trial ◽  
Lateral Epicondylitis ◽  
Painful Condition ◽  
Extracorporeal Shockwave Therapy ◽  
Extracorporeal Shockwave ◽  
Shockwave Therapy ◽  
Vas Score ◽  
Randomised Controlled

Background: Lateral epicondylitis also known as the tennis elbow is a painful condition of the elbow caused by overuse. The disease imparts significant disability to those affected in terms of the quantity and quality of work done.Methods: A randomised controlled trial was conducted in the Department of Physical Medicine and Rehabilitation, RIMS, Imphal for a period of 1 year from February 2017 to January 2018. Eighty-four patients with resistant lateral epicondylitis recruited were divided into 2 groups- group A received Prolozone injection while group B underwent Extracorporeal Shockwave Therapy (ESWT).Results: Assessments of VAS (Visual Analog Scale) and PRTEE (Patient Rated Tennis Elbow Evaluation) were done at 8 weeks and 24 weeks. The mean VAS score in Prolozone group improved from 7.22±0.89 to 4.04±1.01 at 8 weeks to 1.67±0.70 at end of 24 weeks. In ESWT group, mean VAS score improved to 3.91±0.72 at 8 weeks and reduced to 2.3±0.68 at end of 24 weeks. PRTEE improved significantly in both the groups, from 85.33±3.29 to 24.87±2.10 in Prolozone group, and from 85.17±2.83 to 41.89±3.17 in ESWT group.Conclusions: The improvement in pain and disability is better in prolozone group than ESWT (p<0.05) in chronic lateral epicondylitis.

scholarly journals Randomised controlled trial for high-dose intravenous zinc as adjunctive therapy in SARS-CoV-2 (COVID-19) positive critically ill patients: trial protocol

BMJ Open ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. e040580
Author(s):  
Marlon Perera ◽  
John El Khoury ◽  
Vidyasagar Chinni ◽  
Damien Bolton ◽  
Liang Qu ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
Respiratory Illness ◽  
Organ Injury ◽  
High Dose ◽  
Protective Effects ◽  
Double Blind ◽  
Hospitalised Patients ◽  
Randomised Controlled ◽  
Ventilated Patients

IntroductionSARS-CoV-2 (COVID-19) has caused an international pandemic of respiratory illness, resulting in significant healthcare and economic turmoil. To date, no robust vaccine or treatment has been identified. Elemental zinc has previously been demonstrated to have beneficial effects on coronaviruses and other viral respiratory infections due to its effect on RNA polymerase. Additionally, zinc has well-demonstrated protective effects against hypoxic injury—a clear mechanism of end-organ injury in respiratory distress syndrome. We aimed to assess the effect of high-dose intravenous zinc (HDIVZn) on SARS-CoV-2 infection. The end of study analyses will evaluate the reduction of impact of oxygen saturations or requirement of oxygen supplementation.Methods and analysisWe designed a double-blind randomised controlled trial of daily HDIVZn (0.5 mg/kg) versus placebo. Primary outcome measures are lowest oxygen saturation (or greatest level of supplemental oxygenation) for non-ventilated patients and worst PaO2/FiO2 for ventilated patients. Following power calculations, 60 hospitalised patients and 100 ventilated patients will be recruited to demonstrate a 20% difference. The duration of follow-up is up to the point of discharge.Ethics and disseminationEthical approval was obtained through the independent Human Research Ethics Committee. Participant recruitment will commence in May 2020. Results will be published in peer-reviewed medical journals.Trial registration numberACTRN126200000454976.

Sign in / Sign up

Export Citation Format

Share Document